CJC-1295 + Ipamorelin: The Grey Market's Most Popular GH Stack Has Zero Published Evidence

The Most Popular Stack Nobody Has Studied

If you spend any time in peptide communities, telehealth clinic menus, or grey-market vendor catalogs, you’ve seen this combination: CJC-1295 + Ipamorelin. It is, by a wide margin, the most commonly recommended growth hormone secretagogue protocol in the consumer peptide market. Clinics bundle it. Vendors sell pre-mixed vials. Reddit threads analyze dosing schedules in granular detail.

There’s just one problem: no published study has ever evaluated this combination in humans — or in animals, for that matter. The most popular GH secretagogue protocol on the market rests on pharmacological reasoning, community anecdote, and clinical intuition. The published evidence base is zero.

This profile examines what we know, what we don’t know, and what the actual basis is for this combination’s dominance.

---

The Pharmacological Rationale

Why Combine GHRH + Ghrelin Mimetics?

The reasoning behind combining CJC-1295 and ipamorelin is rooted in legitimate endocrinology. Growth hormone release from the anterior pituitary is controlled by two primary stimulatory pathways:

GHRH pathway: Growth hormone-releasing hormone (GHRH) binds GHRH receptors on somatotroph cells, stimulating GH synthesis and release via cAMP signaling. CJC-1295 is a modified GHRH analogue (Mod GRF 1-29, amino acids 1-29 of GHRH with four amino acid substitutions for protease resistance) that activates this pathway.

Ghrelin/GHSR pathway: Ghrelin binds the growth hormone secretagogue receptor (GHSR-1a) on somatotrophs, stimulating GH release via a different intracellular cascade (IP3/DAG pathway). Ipamorelin is a synthetic ghrelin mimetic (pentapeptide, Aib-His-D-2Nal-D-Phe-Lys-NH2) that activates this pathway with notable selectivity — it triggers GH release without significantly affecting cortisol, prolactin, or ACTH at therapeutic doses.

The synergy hypothesis: Because these two pathways converge on somatotroph cells through different receptor-effector cascades, simultaneous activation should — in theory — produce additive or synergistic GH release that exceeds what either peptide alone achieves. The GHRH signal sets the amplitude of GH pulses, while the ghrelin signal amplifies the frequency and magnitude.

This synergy has been demonstrated in published research — but not with CJC-1295 and ipamorelin specifically. The foundational work used native GHRH combined with other GH secretagogues:

Bowers CY et al. (J Clin Endocrinol Metab, 1990;70(4):975–982): Demonstrated that combining GHRH with GHRP-6 (another ghrelin mimetic, different from ipamorelin) produced synergistic GH release in humans — the combined response exceeded the sum of individual responses.

Veldhuis JD et al. (J Clin Endocrinol Metab, 2004;89(2):718–726): Confirmed GHRH + GHRP synergy using hexarelin in older adults, demonstrating that the synergistic effect persists even in the aging pituitary with reduced somatotroph reserve.

Hataya Y et al. (J Clin Endocrinol Metab, 2001;86(9):4552–4555): Showed GHRH + ghrelin combination produced markedly greater GH responses than either stimulus alone.

The Extrapolation Problem

The research above validates the principle of GHRH + ghrelin pathway synergy. But the specific extrapolation to CJC-1295 (without DAC) + ipamorelin involves several unvalidated assumptions:

1. That CJC-1295 without DAC behaves like native GHRH at the receptor level. Likely true given the structural similarity, but Mod GRF 1-29’s four amino acid substitutions have not been pharmacologically characterized in humans.

2. That ipamorelin behaves like GHRP-6 or ghrelin in the synergy paradigm. Ipamorelin is a more selective agonist than GHRP-6, which means it may produce different synergistic dynamics. Its selectivity advantage (less cortisol and prolactin disruption) might also mean less total GH stimulation at equivalent receptor occupancy.

3. That the dose ratios used in community protocols produce the synergistic response observed in clinical studies. The published synergy data used specific dose combinations determined through formal dose-finding. Community protocols (typically 100-200 mcg CJC-1295 + 200-300 mcg ipamorelin, 2-3x daily) were not derived from dose-response studies.

4. That chronic daily administration produces the same effect as the single-dose paradigms studied. Tachyphylaxis (reduced response with repeated dosing) is a known concern with GH secretagogues. Whether the ipa/CJC combination maintains synergy over weeks or months of daily use is unknown.

---

Individual Component Evidence

CJC-1295

The version most people use has no human data. CJC-1295 exists in two forms: with DAC (Drug Affinity Complex, half-life ~6-8 days) and without DAC (also called Mod GRF 1-29, half-life ~30 minutes). The grey market overwhelmingly uses the no-DAC version because its shorter half-life allows pulsatile dosing that mimics natural GH secretion patterns.

The only published human study — Teichman SL et al. (J Clin Endocrinol Metab, 2006;91(3):799–805) — used the DAC version in 62 healthy subjects as a single-dose escalation study. It showed dose-dependent GH elevation lasting up to 6 days with a single injection. The clinical development program was subsequently abandoned.

For CJC-1295 without DAC: zero published human pharmacokinetic data, zero published human pharmacodynamic data, zero safety data. The version most people inject has never been formally characterized in humans.

For our full analysis, see our CJC-1295 profile.

Ipamorelin

Ipamorelin has more human data than CJC-1295 but less than most people assume. Novo Nordisk developed ipamorelin through Phase II clinical trials for post-operative ileus (delayed bowel recovery after surgery). The Phase III trial failed to meet its primary endpoint and the program was abandoned.

The key pharmacological study — Raun K et al. (Eur J Endocrinol, 1998;139(5):552–561) — established ipamorelin’s selectivity profile in swine: potent, dose-dependent GH release with minimal cortisol, prolactin, FSH, LH, or TSH effects even at high doses.

No published body composition trial. No published long-term safety data. No published study for any consumer-relevant endpoint (muscle growth, fat loss, anti-aging, recovery).

For our full analysis, see our ipamorelin profile.

---

What the Community Protocols Actually Look Like

Since published dosing guidance for this combination doesn’t exist, community protocols are worth examining — not as evidence, but as documentation of what people are actually doing.

Typical Grey-Market Protocol

Dosing: 100-200 mcg CJC-1295 (no DAC) + 200-300 mcg ipamorelin per injection, administered subcutaneously.

Frequency: 2-3 times daily, with the most common schedule being morning (upon waking), post-workout (if applicable), and before bed. The pre-bed dose is emphasized in community discussions because natural GH secretion peaks during slow-wave sleep, and the hypothesis is that peptide-stimulated release compounds with the physiological pulse.

Timing: Injected on an empty stomach, with guidance to avoid food (especially carbohydrates and fats) for 30 minutes before and after injection. The rationale is that insulin elevation suppresses GH release, so a fed state would blunt the peptide-stimulated response. This reasoning is pharmacologically sound — insulin and GH are counter-regulatory hormones.

Cycle length: Typically 8-12 weeks, with some users running longer. Cycling rationale is to prevent potential tachyphylaxis and allow pituitary recovery, though no data supports specific on/off durations.

Reconstitution: Both peptides are supplied as lyophilized (freeze-dried) powders requiring reconstitution with bacteriostatic water. Standard reconstitution ratios vary by vendor-supplied vial size but typically aim for concentrations that make dosing math straightforward.

Telehealth Clinic Protocols

Before the Category 2 classification took effect, many telehealth clinics offering peptide therapy prescribed the ipa/CJC combination. Typical clinic protocols tended toward:

• Lower individual doses than grey-market community protocols (often 100 mcg CJC-1295 + 100-200 mcg ipamorelin)
• Twice-daily rather than three-times-daily administration
• Required baseline and follow-up lab work (IGF-1, fasting glucose, insulin, comprehensive metabolic panel)
• 12-week initial cycles with re-evaluation

The clinic protocols were not evidence-based in the sense of being derived from clinical trials, but they generally reflected a more conservative approach than community self-experimentation.

---

Safety Profile: What We Know and Don’t Know

Known (From Individual Components)

Ipamorelin (from Phase I/II data and clinical use): Generally well-tolerated at therapeutic doses. Injection site reactions, transient headache, nausea. The selectivity profile means less cortisol and prolactin disruption than GHRP-6 or GHRP-2. The “GH flush” — warm sensation, facial flushing, tingling in extremities — is commonly reported within 5-15 minutes of injection and is likely related to GH-mediated vasodilation.

CJC-1295 with DAC (from the single published study): Mild injection site reactions, transient headache, diarrhea, nausea. No serious adverse events in the 62-subject dose-escalation study. Single-dose data only.

Unknown (No Published Data)

• Combination safety: No data exists on whether combining CJC-1295 and ipamorelin changes the side effect profile of either compound. Total GH output from the combination may substantially exceed what either produces alone, which means GH-related side effects (water retention, joint pain, insulin resistance, carpal tunnel symptoms) may be amplified.

• Chronic use effects: No long-term safety data exists for either peptide individually, let alone the combination. The theoretical concerns center on sustained GH/IGF-1 elevation:

  • Insulin resistance: GH is a counter-regulatory hormone to insulin. Chronic GH elevation can impair glucose metabolism.
  • Fluid retention: GH promotes sodium and water retention through renal mechanisms.
  • Joint and connective tissue effects: Chronic GH elevation can produce carpal tunnel syndrome and joint pain.
  • Theoretical cancer concerns: IGF-1 is a proliferative and anti-apoptotic growth factor. Chronic IGF-1 elevation is epidemiologically associated with increased risk of certain cancers (colorectal, prostate, breast). Whether peptide-induced IGF-1 elevation carries the same risk is unknown, but the biological plausibility is real.

• Tachyphylaxis: Whether the pituitary response to ipa/CJC diminishes over weeks or months of daily use has not been studied. Anecdotal community reports are mixed — some users report sustained benefits, others describe diminishing effects over time.

• Interactions: No data on interactions with other medications, supplements, or hormones. Users of testosterone replacement therapy commonly add ipa/CJC, but this combination has never been evaluated.

---

Legal and Regulatory Status

FDA classification (as of March 2026): Both CJC-1295 and ipamorelin are classified as Category 2 bulk drug substances, meaning they cannot be legally compounded by 503A or 503B pharmacies. However, HHS Secretary Kennedy announced on February 27, 2026, that approximately 14 Category 2 peptides would be reclassified back to Category 1. CJC-1295 was specifically named among those expected to return to compounding eligibility. Ipamorelin’s reclassification status is less certain — some analysts have speculated it may remain restricted.

Important caveat: The reclassification has been announced but not yet formally published. Until the FDA officially updates the Category 2 list, the legal status remains unchanged. See our March 2026 Regulatory Roundup for full analysis.

WADA status: Both peptides are prohibited under S2.2.4 (Growth Hormone Releasing Factors) at all times, in and out of competition. Athletes subject to anti-doping testing cannot use this combination.

Grey-market availability: The ipa/CJC combination remains widely available from research chemical vendors, typically at $40-80 per combination set (5mg each). Some vendors sell pre-mixed “blend” vials. The standard “research use only” disclaimers apply — and as we’ve documented, the FDA considers these disclaimers a “ruse” when products are clearly intended for human use.

---

Comparison: Ipa/CJC vs. Sermorelin vs. GH Injections

Factor	CJC-1295 + Ipamorelin	Sermorelin	Recombinant GH (Somatropin)
Mechanism	GHRH analogue + ghrelin mimetic	GHRH analogue only	Direct GH replacement
Evidence for combination	None (zero published studies)	N/A (monotherapy)	Extensive (decades of clinical use)
Prior FDA approval	Neither peptide, ever	Yes (Geref, withdrawn 2008)	Yes (multiple brands)
FDA compounding status	Category 2 (reclassification pending)	Category 1	N/A (commercially available)
Published human studies	Zero for the combination	Multiple adult and pediatric studies	Thousands
Preserves pulsatile GH release	Theoretically yes	Yes (documented)	No (exogenous replacement)
Suppresses endogenous GH	Theoretically no	No (documented)	Yes (negative feedback)
Cost (grey market)	~$40-80/month	~$30-60/month	~$500-1,500+/month
Cost (clinical)	Not currently available	~$200-400/month	~$800-2,000+/month

The case for ipa/CJC over sermorelin is primarily pharmacological: the dual-pathway stimulation should produce greater GH output than GHRH stimulation alone, and ipamorelin’s selectivity avoids the cortisol and prolactin issues associated with older ghrelin mimetics. The case against it is evidential: sermorelin has a documented clinical history, prior FDA approval, Category 1 legal status, and published adult human data. CJC-1295 (without DAC) has none of these, and the combination has zero data.

---

Common Vendor Claims vs. Reality

What vendors say	What the evidence shows
”Clinically proven GH-boosting stack”	Zero clinical studies on this combination exist
”Synergistic effect — better than either alone”	GHRH+GHRP synergy is proven with different compounds at different doses; not with this specific combination
”Builds lean muscle and burns fat”	No body composition trial has been conducted with this combination or with either individual component
”Safe and well-tolerated”	Safety profile of the combination is unknown; individual component data is limited to short-term use
”Anti-aging benefits”	No anti-aging endpoint has been studied for this combination
”Better than growth hormone injections”	No head-to-head comparison exists. This is a hypothesis, not a finding
”Preserves natural GH pulsatility”	Mechanistically plausible but not studied for this specific combination

---

The Bottom Line

The CJC-1295 + ipamorelin combination is the peptide market’s most popular growth hormone secretagogue protocol, and its dominance is based on pharmacological reasoning that is genuinely sound. The principle of GHRH + ghrelin mimetic synergy is well-established in published research. Ipamorelin’s selectivity profile is a real pharmacological advantage. The theoretical case for this combination is legitimate.

But theory and evidence are different things. The specific combination at the doses and schedules used in the community has never been evaluated. Not in a clinical trial. Not in an animal study. Not even in a case report. The total published evidence base for the protocol millions of people discuss, purchase, and inject is zero.

If and when these peptides return to Category 1 compounding status, the access pathway improves — licensed pharmacies with quality controls are materially safer than grey-market vials of unknown provenance. But legal access doesn’t create evidence. The clinical gaps remain until someone runs the trials.

For consumers choosing a GH secretagogue approach, the honest comparison is this: sermorelin has prior FDA approval, Category 1 status, published human data, and a characterized safety profile. The ipa/CJC combination has a stronger theoretical rationale for GH output but zero supporting data. Whether the theoretical upside justifies the evidential downside is a decision that should be made with a qualified physician, not a vendor or a Reddit thread.

---

For individual component analysis, see our profiles on CJC-1295 and Ipamorelin. For regulatory context, see our March 2026 Regulatory Roundup.